Journal of Integrative Oncology

Catherine Jones

Publications

• Case Report
  Emergence of Squamous Cell Carcinoma during Treatment of Basal Cell Carcinoma with Vismodegib
  Author(s): Nattamol Hosiriluck and Catherine JonesNattamol Hosiriluck and Catherine Jones
  
  Introduction: Basal cell carcinoma accounts for 80% of all non-melanoma skin cancer. Vismodegib is the hedgehog signaling pathway inhibitor, which has shown improved outcome in both locally advanced and metastatic basal cell carcinoma. There are, however, reports of cutaneous squamous cell carcinomas developing while on active treatment with vismodegib. We present a case of transition to squamous cell carcinoma after vismodegib treatment in a patient with a 10-year history of basal cell carcinoma. Case presentation: 44-year-old Caucasian man with 10 year history of basal cell carcinoma on his left chest wall and left shoulder was treated with local resection and actively on vismodegib. He presented with enlarging and infected mass. He underwent left forequarter amputation of his left arm, shoulder and clavicle. Pathology reported basosquamous cell carcinoma with scapula invasion.. Read More»
  DOI: 10.4172/2329-6771.1000169

  Abstract PDF